Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, TX.
Sierra Eye Associates, Reno, NV.
Asia Pac J Ophthalmol (Phila). 2021 Jan 28;10(4):408-416. doi: 10.1097/APO.0000000000000355.
Age-related macular degeneration (AMD) is one of the most common causes of severe vision loss in the developed world. Advanced forms of AMD are seen in primarily 2 types, exudative AMD involving the presence of choroidal neovascularization and nonexudative or dry AMD with geographic atrophy. For the latter, the combination of vitamins and minerals known as the Age-Related Eye Disease Study-2 formulation has been shown to decrease the rate of progression of nonexudative to exudative AMD, as no other treatments are currently approved for nonexudative AMD. This review will highlight upcoming treatments for nonexudative AMD. Six upcoming agents have shown results at least in the 2A phase. This includes intravitreal agents that are inhibitors of integrin (Risuteganib), intravitreal agents that disrupt the complement pathway (Zimura, APL-2), neuroprotective implants (Brimonidine DDS), a subcutaneous injectable (Elamipretide), and photobiomodulation (Valeda Light Delivery System).
年龄相关性黄斑变性（AMD）是发达国家最常见的严重视力丧失原因之一。晚期 AMD 主要有 2 种类型，渗出性 AMD 涉及脉络膜新生血管的存在，非渗出性或干性 AMD 伴有地图状萎缩。对于后者，被称为年龄相关性眼病研究-2 配方的维生素和矿物质组合已被证明可降低非渗出性 AMD 向渗出性 AMD 进展的速度，因为目前尚无其他治疗方法被批准用于非渗出性 AMD。本综述将重点介绍非渗出性 AMD 的新治疗方法。至少在 2A 期，有 6 种新的药物显示出了结果。这包括整合素抑制剂（Risuteganib）、破坏补体途径的眼内药物（Zimura、APL-2）、神经保护植入物（Brimonidine DDS）、皮下注射剂（Elamipretide）和光生物调节（Valeda Light Delivery System）。
